Neoral: Advanced Immunosuppression for Transplant Success
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $8.34 | $83.37 (0%) | 🛒 Add to cart |
| 20 | $6.68 | $166.74 $133.59 (20%) | 🛒 Add to cart |
| 30 | $5.73 | $250.11 $171.76 (31%) | 🛒 Add to cart |
| 60 | $5.62 | $500.21 $337.49 (33%) | 🛒 Add to cart |
| 90 | $5.52 | $750.32 $497.20 (34%) | 🛒 Add to cart |
| 120 | $5.42 | $1000.42 $650.88 (35%) | 🛒 Add to cart |
| 180 | $5.32 | $1500.63 $958.24 (36%) | 🛒 Add to cart |
| 270 | $5.22 | $2250.95 $1410.23 (37%) | 🛒 Add to cart |
| 360 | $5.02
Best per pill | $3001.27 $1807.99 (40%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.52 | $45.20 (0%) | 🛒 Add to cart |
| 20 | $3.52 | $90.40 $70.31 (22%) | 🛒 Add to cart |
| 30 | $3.31 | $135.60 $99.44 (27%) | 🛒 Add to cart |
| 60 | $2.86 | $271.20 $171.76 (37%) | 🛒 Add to cart |
| 90 | $2.71 | $406.80 $244.08 (40%) | 🛒 Add to cart |
| 120 | $2.61 | $542.40 $313.39 (42%) | 🛒 Add to cart |
| 180 | $2.51 | $813.60 $452.00 (44%) | 🛒 Add to cart |
| 270 | $2.41 | $1220.40 $650.88 (47%) | 🛒 Add to cart |
| 360 | $2.31
Best per pill | $1627.19 $831.68 (49%) | 🛒 Add to cart |
Synonyms | |||
Neoral (cyclosporine, modified) is a critical immunosuppressive agent formulated to prevent organ rejection in transplant recipients. Its advanced microemulsion technology ensures more predictable absorption and consistent blood levels compared to earlier formulations. This medication is a cornerstone of post-transplant therapy, offering patients and clinicians a reliable option for long-term graft survival. By selectively inhibiting T-cell activation, Neoral provides targeted immune modulation while minimizing broader immunosuppressive effects.
Features
- Microemulsion formulation for improved bioavailability
- Consistent and predictable pharmacokinetic profile
- Available in 25 mg and 100 mg soft gelatin capsules
- Oral solution formulation for flexible dosing (100 mg/mL)
- Temperature-stable composition (15-30°C)
- Child-resistant packaging options
Benefits
- Significantly reduces risk of acute organ rejection in transplant patients
- Provides stable blood concentration levels for consistent immunosuppression
- Allows for precise dosage titration based on therapeutic drug monitoring
- Demonstrates favorable long-term graft survival rates across transplant types
- Offers flexible administration options for varied patient needs
- Maintains efficacy with reduced interpatient variability compared to sandimmune formulation
Common use
Neoral is primarily indicated for the prophylaxis of organ rejection in patients receiving kidney, liver, and heart allogeneic transplants. It is typically used as part of a comprehensive immunosuppressive regimen that may include corticosteroids and other immunosuppressive agents. The medication may also be prescribed for severe, active rheumatoid arthritis where conventional therapy has proven inadequate, and for severe psoriasis in adult non-immunocompromised patients when other systemic therapies have failed or are contraindicated.
Dosage and direction
Initial dosing must be individualized based on patient weight, transplant type, and concomitant immunosuppressive therapy. For transplant patients, the initial oral dose typically ranges from 8-18 mg/kg/day, administered in two divided doses, beginning 4-12 hours prior to transplantation. Subsequent dosing is adjusted based on cyclosporine blood concentration monitoring, with target trough levels varying by transplant type and postoperative timing.
Dosage should be administered consistently with regard to meals, preferably at the same times each day. The oral solution should be diluted with orange or apple juice (preferably at room temperature) immediately before administration to improve palatability. Grapefruit juice should be avoided as it affects cyclosporine metabolism.
Regular therapeutic drug monitoring is essential, particularly during the first few months post-transplant when dosage requirements may change frequently. Dosage adjustments should be made gradually under close medical supervision.
Precautions
Patients require regular monitoring of blood pressure, renal function, and cyclosporine blood levels. Serum creatinine should be measured at least twice weekly during initial therapy and regularly thereafter. Liver function tests, serum potassium, magnesium, and lipid profiles should be monitored periodically.
Vaccination may be less effective during therapy; live vaccines should generally be avoided. Patients should be advised that immunosuppression may increase susceptibility to infections and the possible risk of lymphoma and other malignancies. Adequate hydration should be maintained, particularly during hot weather or physical exertion.
Skin should be protected from excessive sunlight due to increased photosensitivity. Regular dermatological examinations are recommended for early detection of premalignant lesions.
Contraindications
Neoral is contraindicated in patients with hypersensitivity to cyclosporine or any component of the formulation. It should not be used with potassium-sparing diuretics in patients with hyperkalemia or in patients receiving other nephrotoxic drugs unless the benefits outweigh the risks. Concomitant use with strong CYP3A4 inhibitors or inducers requires extreme caution and likely contraindicates Neoral therapy.
Possible side effect
Common adverse reactions include hypertension (25-50%), renal dysfunction (25-40%), tremor (20-30%), hirsutism (15-45%), gum hyperplasia (10-30%), and gastrointestinal disturbances (15-30%). Hyperlipidemia occurs in approximately 15-25% of patients.
More serious but less frequent side effects include nephrotoxicity, hepatotoxicity, neurotoxicity (including seizures and encephalopathy), and thrombotic microangiopathy. Opportunistic infections may occur due to immunosuppression. Laboratory abnormalities may include hyperkalemia, hypomagnesemia, and hyperuricemia.
Drug interaction
Neoral interacts significantly with numerous medications through CYP3A4 metabolism and P-glycoprotein transport. Strong inhibitors of CYP3A4 (ketoconazole, clarithromycin, ritonavir) can increase cyclosporine levels 2-5 fold. Inducers (rifampin, phenytoin, St. John’s wort) can decrease levels by 50-80%.
Other significant interactions include increased nephrotoxicity with NSAIDs, aminoglycosides, and amphotericin B; additive neurotoxicity with methylprednisolone; and potential for serious hyperkalemia with potassium-sparing diuretics or ACE inhibitors. Grapefruit juice inhibits CYP3A4 and should be avoided.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. Patients should never double the dose to make up for a missed one. Consistency in dosing schedule is critical for maintaining stable blood levels. If multiple doses are missed, patients should contact their healthcare provider immediately for guidance, as subtherapeutic levels could increase rejection risk.
Overdose
Symptoms of overdose may include nausea, vomiting, lethargy, headache, and electrolyte disturbances. More severe overdose can lead to renal impairment, hepatotoxicity, and seizures. Management involves immediate gastric lavage if ingestion was recent, followed by activated charcoal. Supportive measures should include monitoring of renal and hepatic function, electrolyte balance, and cyclosporine blood levels. Hemodialysis is not effective for removal due to high protein binding and extensive tissue distribution.
Storage
Store at room temperature between 15-30°C (59-86°F). Protect from light and moisture. Keep the oral solution in the original container; do not transfer to other containers. The diluted oral solution should be used immediately after preparation. Keep all medications out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made by qualified healthcare professionals based on individual patient circumstances. Dosage and administration must be determined by a physician familiar with the patient’s medical history and current condition. Patients should not alter their medication regimen without consulting their healthcare provider.
Reviews
Clinical studies demonstrate Neoral’s efficacy in preventing rejection, with one-year kidney graft survival rates exceeding 90% in combination therapy. Physicians report appreciation for its predictable pharmacokinetics compared to previous formulations. Patients note the importance of consistent dosing and monitoring, though some report challenges with side effect management. Long-term data supports its role in maintenance immunosuppression, though optimal dosing strategies continue to be refined through ongoing research.